Viridian Therapeutics, Inc.\DE 8-K

What Happened

• Viridian Therapeutics, Inc. announced on May 11, 2026 that it closed two financing transactions: a $250.0 million aggregate principal amount offering of 1.75% Convertible Senior Notes due 2032 (including the full $25.0M overallotment) and an equity offering that raised approximately $117.0 million net (7,352,942 shares at $17.00 per share, with a 30‑day option for additional shares). The convertible notes were issued under an indenture with U.S. Bank Trust Company, N.A. as trustee. The company filed the related underwriting agreements and legal opinions as exhibits to the Form 8‑K.

Key Details

• Convertible notes: $250.0M aggregate principal, 1.75% interest paid semiannually, maturity May 15, 2032; net proceeds ≈ $242.0M (after fees and expenses).
• Conversion terms: initial conversion rate 40.5680 shares per $1,000 principal (≈ $24.65 per share); maximum initial shares potentially issuable up to 14,705,875 (subject to anti‑dilution adjustments).
• Equity offering: 7,352,942 shares sold at $17.00 per share; underwriters’ option for an additional 1,102,941 shares; net proceeds ≈ $117.0M.
• Use of proceeds: repay all outstanding borrowings under the Hercules Capital loan facility, fund market expansion studies for its thyroid eye disease franchise, advance earlier-stage R&D, and for working capital and general corporate purposes.

Why It Matters

• The financings significantly boost Viridian’s cash position and reduce near‑term leverage by repaying its Hercules loan, giving the company capital to advance its thyroid eye disease program and other R&D efforts.
• The convertible notes dilute shareholders only if converted; conversion and redemption mechanics (including a conversion price ~ $24.65/share and conversion/repurchase rights on certain corporate events) define when dilution could occur and at what rate.
• Investors should note interest rate, maturity (2032), conversion triggers, and the company’s stated uses of proceeds; these are material to Viridian’s capital structure and potential share count over time.